抗血管生成药物治疗肺癌脑转移的研究新进展

doi:10.11904/j.issn.1002-3070.2021.01.019

摘要/Abstract

摘要： 晚期肺癌脑转移发生率高,预后差。近年来,随着肺癌总体治疗的发展,为晚期肺癌脑转移提供了更多的治疗手段和期待。目前的临床研究提示抗血管生成药物在肺癌脑转移的治疗中占有重要地位,从大分子的单克隆抗体,到泛靶点抗血管药物,再到小分子酪氨酸激酶抑制剂(Tyrosine kinase inhibitor,TKI),均显示出一定的疗效与良好的安全性,并与化疗、放疗以及表皮生长因子受体酪氨酸激酶抑制剂(Epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)表现出良好的协同抗肿瘤作用。本文就抗血管生成药物治疗肺癌脑转移的研究新进展做一综述。

关键词: 抗血管生成, 肺癌, 脑转移

Abstract: The incidence of brain metastases in advanced lung cancer is high and the prognosis is poor.In recent years,with the development of overall treatment for lung cancer,more treatments and expectations have been provided for advanced lung cancer with brain metastases.Current clinical studies suggest that antiangiogenic drugs play an important role in the treatment of lung cancer with brain metastasis including from monoclonal antibody to multi-target antiangiogenic drugs and then to small molecule tyrosine kinase inhibitor(TKI).These drugs have shown a certain efficacy and good safety,and they also show a significantly synergistic anti-tumor effect on chemotherapy,radiotherapy and epidermal growth factor receptor TKI(EGFR-TKI).This article reviews the new progress of anti-angiogenic drugs in the treatment of lung cancer with brain metastases.

Key words: Antiangiogenesis, Lung cancer, Brain metastases

中图分类号:

R734.2

鲍瑜,朱立建(综述),钱江(审校). 抗血管生成药物治疗肺癌脑转移的研究新进展[J]. 实用肿瘤学杂志, 2021, 35(1): 91-96.

BAO Yu,ZHU Lijian,QIAN Jiang. New progress in the research of anti-angiogenic drugs in the treatment of lung cancer with brain metastases[J]. Journal of Practical Oncology, 2021, 35(1): 91-96.

参考文献

1 Villano JL,Durbin EB,Normandeau C,et al.Incidence of brain metastasis at initial presentation of lung cancer[J].Neuro Oncol,2015,17(1):122-128.
2 Goncalves PH,Peterson SL,Vigneau FD,et al.Risk of brain metastases in patients with nonmetastatic lung cancer:analysis of the Metropolitan Detroit Surveillance,Epidemiology,and End Results(SEER)data[J].Cancer,2016,122(12):1921-1927.
3 中国临床肿瘤学会,中国抗癌协会肺癌专业委员会.肺癌脑(膜)转移诊断治疗共识[J].循证医学,2018,18(4):193-201.
4 代欣,张大昕.非小细胞肺癌抗血管生成治疗研究现状[J].实用肿瘤学杂志,2017,31(5):472-475.
5 杨珑静,马洪波,张献全,等.抗血管生成药物在非小细胞肺癌中的应用及研究进展[J].医学信息,2019,32(8):58-66.
6 Hanibuchi M,Kim SJ,Fidler IJ,et al.The molecular biology of lung cancer brain metastasis:an overview of current comprehensions and future perspectives[J].J Med Invest,2014,61(3/4):241-253.
7 Lee SH,Jeong D,Han YS,et al.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis[J].Ann Surg Treat Res,2015,89(1):1-8.
8 Sandler A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,355(24):2542-2550.
9 Reck M,von Pawel J,Zatloukal P,et al.Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer:AVAil[J].J Clin Oncol,2009,27(8):1227-1234.
10 Zhou C,Wu YL,Chen G,et al.BEYOND:a randomized,double-blind,placebo-controlled,multicenter,phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2015,33(19):2197-2204.
11 Besse B,Lasserre SF,Compton P,et al.Bevacizumab safety in patients with central nervous system metastases[J].Clin Cancer Res,2010,16(1):269-278.
12 Besse B,Le Moulec S,Mazières J,et al.Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic,untreated brain metastases(BRAIN):a nonrandomized,phase II study[J].Clin Cancer Res,2015,21(8):1896-1903.
13 Stefanou D,Stamatopoulou S,Sakellaropoulou A,et al.Bevacizumab,pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients:focus on patients with brain metastases[J].Oncol Lett,2016,12(6):4635-4642.
14 Tian Y,Zhai X,Tian H,et al.Bevacizumab in combination with pemetrexed and platinum significantly improved the clinical outcome of patients with advanced adenocarcinoma NSCLC and brain metastases[J].Cancer Manag Res,2019,11:10083-10092.
15 Gubens MA,Chuang JC,Akerley W,et al.A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy[J].J Thorac Dis,2018,10(1):219-227.
16 Wang Z,Yang JJ,Tu HY,et al.Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases[J].Int J Clin Oncol,2019,25(2):267-273.
17 Chikaishi Y,Kanayama M,Taira A,et al.Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer[J].Ann Transl Med,2018,6(20):401-407.
18 Yang RF,Yu B,Zhang RQ,et al.Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small cell lung cancer[J].Braz J Med Biol Res,2017,51(1):6073-6081.
19 Jiang T,Zhang Y,Li X,et al.EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases[J].Eur J Cancer,2019,121:98-108.
20 Lévy C,Allouache D,Lacroix J,et al.REBECA:a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain m etastasis from solid tumours[J].Ann Oncol,2014,25(12):2351-2357.
21 潘绵顺,李勇,邱书珺,等.SRT联合贝伐珠单抗治疗肺腺癌脑转移瘤的疗效评估[J].中华放射肿瘤学杂志,2017,26(8):880-883.
22 Uprety D.Clinical utility of ramucirumab in non-small cell lung cancer[J].Biologics,2019,13:133-137.
23 Tanimura K,Uchino J,Tamiya N,et al.Treatment rationale and design of the RAMNITA study[J].Medicine,2018,97(23):e11084.
24 王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290.
25 吴竞,樊锐太,王鑫,等.重组人血管内皮抑素联合放化疗治疗非小细胞肺癌脑转移[J].河南医学研究,2014,23(1):51-53.
26 Jiang X,Ding M,Qiao Y,et al.Recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer[J].Clin Transl Oncol,2014,16(7):630-636.
27 Knisely JP,Berkey B,Chakravarti A,et al.A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases(RTOG 0118)[J].Int J Radiat Oncol Biol Phys,2008,71(1):79-86.
28 刘建刚,施朕善,徐珊珊,等.沙利度胺联合放疗治疗晚期非小细胞肺癌脑转移临床疗效观察[J].临床肺科杂志,2018,23(6):1010-1012.
29 Lee SM,Rudd R,Woll PJ,et al.Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer[J].J Clin Oncol,2009,27(31):5248-5254.
30 Liu Y,He S,Ding Y,et al.The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer:a meta-analysis[J].Contemp Oncol(Pozn),2014,18(1):39-47.
31 Wu F,Zhang S,Xiong A,et al.A phase II clinical trial of apatinib in pretreated advanced non-squamous non-small cell Lung Cancer[J].Clin Lung Cancer,2018,19(6):831-842.
32 Yu GC,Yang J,Ye B,et al.Apatinib in the treatment of advanced non-small-cell lung cancer:A meta-analysis[J].Math Biosci Eng,2019,16(6):7659-7670.
33 Leng J,Li DR,Huang LM,et al.Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer:a retrospective analysis in a real-world setting[J].Medicine(Baltimore),2019,98(36):16967-1683.
34 张智显,顾后,林劼,等.伽玛刀联合阿帕替尼及替莫唑胺治疗肺癌脑转移的疗效[J].昆明医科大学学报,2018,39(12):65-68.
35 张智显,顾后,林劫,等.阿帕替尼联合替莫唑安序贯全脑放疗二线治疗小细胞肺癌脑转移[J].昆明医科大学学报,2019,40(8):97-101.
36 Xu J,Liu X,Yang S,et al.Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases[J].Oncol Res,2020,28(2):127-133.
37 Han B,Li K,Wang Q,et al.Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer:the ALTER 0303 Phase 3 randomized clinical trial[J].JAMA Oncol,2018,4(11):1569-1575.
38 Jiang S,Liang H,Liu Z,et al.The impact of anlotinib on brain metastases of non-small cell lung cancer:post hoc analysis of a phase III randomized control trial(ALTER0303)[J].Oncologis,2020[Epub ahead of print].
39 黄行志,蔡凡,刘高,等.安罗替尼联合放疗治疗非小细胞肺癌伴脑转移的临床分析[J].基层医学论坛,2020,24(1):5-7.
40 Wang Y,Wang X,Guan Y,et al.Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer:Rvision-001 study protocol[J].Thorac Cancer,2020,11(5):1361-1364.
41 Paz-Ares L,Hirsh V,Zhang L,et al.Monotherapy administration of sorafenib in patients with non-small cell lung cancer(MISSION)trial:a phase III,multicenter,placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous non-small cell lung cancer after 2 or 3 previous treatment regimens[J].J Thorac Oncol,2015,10(12):1745-1753.
42 Laurie SA,Solomon BJ,Seymour L,et al.Randomised,double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer:NCIC Clinical Trials Group study BR29[J].Eur J Cancer,2014,50(4):706-712.
43 Yoh K,Seto T,Satouchi M,et al.Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer(LURET):an open-label,multicentre phase 2 trial[J].Lancet Respir Med,2017,5(1):42-50.
44 Yoh K,Seto T,Satouchi M,et al.LURET:final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer[J].Ann Oncol,2018,29(Suppl 8):538.
45 Subbiah V,Berry J,Roxas M,et al.Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases[J].Lung Cancer,2015,89(1):76-79.
46 Capelletto E,Migliorino MR,Morabito A,et al.Final results of the SENECA(second line nintedanib in non-small cell lung cancer)trial[J].Lung Cancer,2019,134:210-217.
47 Lu S,Chang J,Liu X,et al.Randomized,double-blind,placebo-controlled,multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced non-squamous non-small cell lung cancer[J].J Clin Oncol,2018,36(12):1207-1217.
48 Yao Y,Zhou Y,Hua Q.Comparing efficacy and safety of regorafenib versus pemetrexed in lung cancer:a preliminary clinical trial evaluating effect of inflammatory biomarkers on disease progression[J].Pak J Pharm Sci,2019,32(3 Special):1293-1299.

[1]	董程(综述),段勇(审校). Dickkopf家族蛋白在非小细胞肺癌中的作用机制和治疗应用的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 64-68.
[2]	闫䶮, 侯利芳, 李任飞, 闫鹏, 王月东, 郑玉婷. ^99mTc-HYNIC-MPG在体非小细胞肺癌分子分型研究[J]. 实用肿瘤学杂志, 2020, 34(5): 412-417.
[3]	程月, 张明岩, 张文博, 徐晖. LncRNAs作为ceRNAs在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 451-455.
[4]	赵仁成, 林子棠, 余卫军, 雷林, 刘峥, 徐英, 郭艳芳, 彭绩. 2017—2019年深圳市宝安区40~74岁常住居民五癌风险流行状况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 315-320.
[5]	孟瑞瑞, 刘圆圆, 官新立, 周鹏, 许国辉. 低剂量螺旋CT肺癌筛查的研究现状与进展[J]. 实用肿瘤学杂志, 2020, 34(4): 372-376.
[6]	陈澜涛, 颜巍, 刘静蕾, 姚磊. 防己诺林碱对肺癌H1299和A549细胞的作用及其分子机制研究[J]. 实用肿瘤学杂志, 2020, 34(2): 126-132.
[7]	朱玉成, 孙昕, 孟丹. 酮咯酸氨丁三醇预防性镇痛对肺癌手术患者免疫功能的影响[J]. 实用肿瘤学杂志, 2020, 34(2): 176-180.
[8]	范庞双, 庞先琼. miR-616通过靶向TIMP-2增强肺癌细胞放射敏感性的机制研究[J]. 实用肿瘤学杂志, 2020, 34(1): 30-36.
[9]	聂建, 陈公琰. 凝血指标在小细胞肺癌中的临床和预后价值:一项回顾性研究[J]. 实用肿瘤学杂志, 2020, 34(1): 49-54.
[10]	梁永琴, 赵宏伟. 抗血管生成药物在铂耐药卵巢癌中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 60-63.
[11]	孙亦鹏, 倪振华, 吴颖颖, 陈清阁, 毕俊杰, 林玉华, 王雄彪. 过表达CLPTM1L降低95-D肺癌细胞对吉西他滨的敏感性[J]. 实用肿瘤学杂志, 2019, 33(6): 486-490.
[12]	李传海, 刘玉, 王延群, 陈英剑. ABL2在肺癌中的作用及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 497-501.
[13]	李剑, 徐向英, 吕研. 局限期小细胞肺癌首程治疗失败后再程治疗的相关研究[J]. 实用肿瘤学杂志, 2019, 33(6): 519-524.
[14]	王静西, 董晓平, 张雪, 贺宇彤. MiR-26a在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 561-565.
[15]	孙亚娟, 姜智允, 尚乃舰, 孙庆鑫, 陆佩欧. 双源CT能量成像在评估非小细胞肺癌纵隔淋巴结转移中的应用价值[J]. 实用肿瘤学杂志, 2019, 33(6): 531-535.